within Pharmacolibrary.Drugs.ATC.D;

model D11AX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.15166666666666667,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0114,
    Tlag           = 960
  );

  annotation(Documentation(
    info ="<html><body><p>Finasteride is a 5-alpha-reductase inhibitor used primarily to treat benign prostatic hyperplasia (BPH) and male pattern hair loss (androgenetic alopecia). It blocks the conversion of testosterone to dihydrotestosterone (DHT), a key factor in prostate enlargement and hair follicle miniaturization. Finasteride is an approved prescription medication, used today for these indications, mainly in adult males.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from healthy adult male volunteers after single oral dose administration.</p><h4>References</h4><ol><li>Aditya K Gupta, Mesbah Talukder, Greg Williams,Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.,The Journal of dermatological treatment,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35920739/'>https://pubmed.ncbi.nlm.nih.gov/35920739/</a></li><li>A K Gupta, M Venkataraman, M Talukder, M A Bamimore,Finasteride for hair loss: a review.,The Journal of dermatological treatment,2022<a href='https://pubmed.ncbi.nlm.nih.gov/34291720/'>https://pubmed.ncbi.nlm.nih.gov/34291720/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D11AX10;
